Overview

A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With DMARDs Versus DMARDs Alone in Patients With Rheumatoid Arthritis

Status:
Unknown status

Trial end date:
2019-12-01

Target enrollment:

Participant gender:

Summary

A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination with DMARDs versus DMARDs Alone in Patients with Rheumatoid Arthritis

Phase:

Phase 3

Details

Lead Sponsor:

Mycenax Biotech Inc.
TSH Biopharm Corporation Limited

Treatments:

Antirheumatic Agents